Drug Profile
Research programme: monoclonal antibodies - Cipla Biotech
Alternative Names: CBT-127; CBT-128Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Cipla BioTec
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Wet age-related macular degeneration
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Wet age-related macular degeneration in India (Parenteral)
- 03 Oct 2023 Discontinued for Breast cancer in India (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in India (Parenteral)